American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Gastroenterology

Volumn 153, Issue 3, 2017, Pages 827-834

  Feuerstein, Joseph D ^a   Nguyen, Geoffrey C ^b,f   Kupfer, Sonia S ^c   Falck Ytter, Yngve ^d   Singh, Siddharth ^e   Gerson, Lauren ^f   Hirano, Ikuo ^f   Rubenstein, Joel H ^f   Smalley, Walter E ^f   Stollman, Neil ^f   Sultan, Shahnaz ^f   Vege, Santhi S ^f   Wani, Sachin B ^f   Weinberg, David ^f   Yang, Yu Xiao ^f  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CHICAGO   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE

Author keywords

6 TGN; 6 thioguanine; AGA; American Gastroenterological Association; CBC; CI; complete blood count; confidence interval; GRADE; Grading of Recommendations Assessment, Development and Evaluation; IBD; inflammatory bowel disease; randomized controlled trial; RCT; relative risk; RR; TDM; therapeutic drug monitoring; thiopurine methyltransferase; TNF; TPMT; tumor necrosis factor

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; DRUG ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

ARTICLE; DRUG CLEARANCE; DRUG MONITORING; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTENTION TO TREAT ANALYSIS; MEDICAL SOCIETY; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE; CONSENSUS; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; PREDICTIVE VALUE; STANDARDS; TREATMENT OUTCOME; UNITED STATES;

ANTI-INFLAMMATORY AGENTS; CONSENSUS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; GASTROENTEROLOGY; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; PREDICTIVE VALUE OF TESTS; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 85028810296     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.07.032     Document Type: Article

References (33)

1. Vande Casteele, N., Herfarth, H., Katz, J., et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology 153 (2017), 835–857.
2. Colombel, J.F., Narula, N., Peyrin-Biroulet, L., Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 152 (2017), 351–361 e5.
3. European Medicines Agency. Guideline on Bioanalytical Method Validation. 2009, European Medicine Agency, London.
4. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2013, US Food and Drug Administration, Silver Springs, MD.
5. Bodini, G., Giannini, E.G., Furnari, M., et al. Comparison of two different techniques to assess adalimumab trough levels in patients with Crohn's disease. J Gastrointestin Liver Dis 24 (2015), 451–456.
6. Graham, R., Mancher, M., Wolman, D.M., et al. Clinical Practice Guidelines We Can Trust. 2011, National Academies Press, Washinton, DC.
7. Sultan, S., Falck-Ytter, Y., Inadomi, J.M., The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol 11 (2013), 329–332.
8. Steenholdt, C., Brynskov, J., Thomsen, O., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. Volume 63 (2014), 919–927.
9. Paul, S., Del Tedesco, E., Marotte, H., et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 19 (2013), 2568–2576.
10. Roblin, X., Marotte, H., Rinaudo, M., et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12 (2014), 80–84.e2.
11. Yanai, H., Lichtenstein, L., Assa, A., et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 13 (2015), 522–530.
12. Ungar, B., Levy, I., Yavne, Y., et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 14 (2016), 550–557.e2.
13. Adedokun, O.J., Sandborn, W.J., Feagan, B.G., et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 147 (2014), 1296–1307.e5.
14. Reinisch, W., Colombel, J.F., Sandborn, W.J., et al. Factors associated with short- and long-term outcomes of therapy for crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 539–547.
15. Arias, M.T., Vande Casteele, N., Vermeire, S., et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 13 (2015), 531–538.
16. Bortlik, M., Duricova, D., Malickova, K., et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 7 (2013), 736–743.
17. Singh, N., Rosenthal, C.J., Melmed, G.Y., et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 20 (2014), 1708–1713.
18. Warman, A., Straathof, J.W.A., Derijks, L.J.J., Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol Hepatol 27 (2015), 242–248.
19. Chaparro, M., Guerra, I., Iborra, M., et al. Correlation between adalimumab serum levels and remission after the induction phase in crohn's disease patients. Gastroenterology 148:Suppl 1 (2015), S107–S108.
20. Frederiksen, M.T., Ainsworth, M.A., Brynskov, J., et al. Antibodies against infliximab (IFX) are associated with de novo development of antibodies to adalimumab (ADL) and therapeutic failure in IFX-to-ADL switchers with inflammatory bowel disease. Inflamm Bowel Dis 20 (2014), 1714–1721.
21. Mazor, Y., Almog, R., Kopylov, U., et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 40 (2014), 620–628.
22. Steenholdt, C., Bendtzen, K., Brynskov, J., et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post-hoc analysis of a randomized controlled trial. Am J Gastroenterol 109 (2014), 1055–1064.
23. Ward, M.G., Kariyawasam, V.C., Mogan, S.B., et al. Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 28 (2013), 100–101.
24. Vande Casteele, N., Ferrante, M., Van Assche, G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148 (2015), 1320–1329.
25. Vaughn, B.P., Martinez-Vazquez, M., Patwardhan, V.R., et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 20 (2014), 1996–2003.
26. Coenen, M.J.H., De Jong, D.J., Van Marrewijk, C.J., et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology 149 (2015), 907–917.
27. Newman, W.G., Payne, K., Tricker, K., et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 12 (2011), 815–826.
28. Sayani, F.A., Prosser, C., Bailey, R.J., et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can J Gastroenterol 19 (2005), 147–151.
29. Lewis, J.D., Abramson, O., Pascua, M., et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 7 (2009), 1195–1201.
30. Haines, M.L., Ajlouni, Y., Irving, P.M., et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 17 (2011), 1301–1307.
31. Reinshagen, M., Schütz, E., Armstrong, V.W., et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 53 (2007), 1306–1314.
32. Van Asseldonk, D.P., Sanderson, J., de Boer, N.K.H., et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease—proceedings of the first Thiopurine Task Force meeting. Digest Liver Dis 43 (2011), 270–276.
33. American Gastroenterological Association. Therapeutic drug monitoring in inflammatory bowel disease––clinical decision support tool. Gastroenterology 153 (2017), 858–859.